Name: ALTAMIRA THERAPEUTICS LTD (CYTO) Stock
Brand: ALTAMIRA THERAPEUTICS LTD
Rating: 4 (3 reviews)

CYTO Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

a year ago - By: Benzinga - Mentions: EVO EXAS PACS GMED ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Provides Update on Nasdaq Listing

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Provides Update on Nasdaq Listing

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances

a year ago - By: InvestorPlace - Mentions: AISP ALBT ARAY DFLI ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

a year ago - By: Benzinga - Mentions: SPRC JZ ALBT ARAY ...

Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management

a year ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management

1 years ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Provides Business Update

1 years ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Provides Business Update

1 years ago - By: FN Media Group LLC - Mentions: ONCY ONC.CA RENB PFE ...

Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

1 years ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal

1 years ago - By: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal

ALTAMIRA THERAPEUTICS LTD (CYTO) Stock News

CYTO Latest News, Press Relases and Analysis